Prelude Therapeutics Incorporated
PRLD
Rank in Stocks
#16288
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company... Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Share Price
$3.76
Last synced: 2026-11-09
Market Cap
$217.63M
Change (1 day)
4.44%
Change (1 year)
178.52%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Prelude Therapeutics Incorporated (PRLD)
Category
Healthcare
EPS for Prelude Therapeutics Incorporated (PRLD)
EPS as of June 2026 TTM: $-0.79
According to Prelude Therapeutics Incorporated's latest financial reports, its current EPS (TTM) is $-0.79. At the end of 2025 the company had an EPS of $-1.29, an increase over its 2024 EPS of $-1.68.
EPS history for Prelude Therapeutics Incorporated from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.79 | -38.76% |
| 2025 | $-1.29 | -23.21% |
| 2024 | $-1.68 | -16.83% |
| 2023 | $-2.02 | -11.01% |
| 2022 | $-2.27 | -2.58% |
| 2021 | $-2.33 | 79.23% |
| 2020 | $-1.30 | 52.94% |
| 2019 | $-0.85 | -90.87% |
| 2018 | $-9.31 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,082.28% |
US
|
|
| $-7.07 | 794.94% |
US
|
|
| $-5.29 | 569.62% |
AU
|
|
| $12.88 | -1,730.39% |
BE
|
|
| $21.56 | -2,829.11% |
NL
|
Questions about Prelude Therapeutics Incorporated's earnings per share (EPS)
What is Prelude Therapeutics Incorporated's earnings per share (EPS)?
Prelude Therapeutics Incorporated's earnings per share (EPS) over the last twelve months is $-0.79, as of Jun 2026.
What was Prelude Therapeutics Incorporated's earnings per share (EPS) in 2025?
In 2025, Prelude Therapeutics Incorporated's earnings per share (EPS) was $-1.29, compared with $-1.68 in 2024.
How has Prelude Therapeutics Incorporated's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Prelude Therapeutics Incorporated's earnings per share (EPS) was highest in 2025 ($-1.29) and lowest in 2021 ($-2.33).
How does Prelude Therapeutics Incorporated's earnings per share (EPS) compare with similar companies?
Prelude Therapeutics Incorporated's earnings per share (EPS) ($-0.79) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.